Phenotypic and genotypic characterization of biofilm-forming ability of Shiga toxin-producing Escherichia coli associated with human infections

Appl Environ Microbiol. 2015 Dec 28. pii: AEM.02983-15. [Epub ahead of print]
 
 
 
 

Abstract

Forming biofilms may be a survival strategy of Shiga toxin-producing Escherichia coli to enable it to persist in the environment and the food industry. Here we evaluate and characterize the biofilm forming ability of 39 isolates of Shiga toxin-producing Escherichia coli recovered from human infection and belonging to seropathotypes A, B or C. The presence and/or production of biofilms factors such as curli, cellulose, autotransporter and fimbriae were investigated. The polymeric matrix of these biofilms was analyzed by confocal microscopy and by enzymatic digestion. Cell viability and matrix integrity were examined after sanitizer treatments. Isolates of the seropathotype A (O157:H7 and O157:NM), which have the highest relative incidence of human infection, had a greater ability to form biofilms than isolates of seropathotype B or C. Seropathotype A isolates were unique in their ability to produce cellulose and poly-N-acetyl glucosamine. The integrity of the biofilms was dependant on proteins. Two autotransporter genes, ehaB and espP, and two fimbriae genes, z1538 and lpf2, were identified as potential genetic determinants for biofilm formation. Interestingly, the ability of several isolates from seropathotype A to form biofilms was associated with their ability to agglutinate yeast in a mannose-independent manner. We consider this an unidentified biofilm-associated factor produced by those isolates. Treatment with sanitizers reduced the viability of Shiga toxin-producing Escherichia coli but did not completely remove the biofilm matrix. Overall, our data indicate that biofilm formation could contribute to the persistence of Shiga toxin-producing Escherichia coli and specifically seropathotype A isolates in the environment.

 

Article

Have more questions? Submit a request

Comments

Powered by Zendesk